Logotype for Filana Therapeutics Inc

Filana Therapeutics (FLNA) Proxy Filing summary

Event summary combining transcript, slides, and related documents.

Logotype for Filana Therapeutics Inc

Proxy Filing summary

2 Dec, 2025

Executive summary

  • The 2025 Annual Meeting will be held virtually on May 23, 2025, with five key proposals up for shareholder vote, including director elections, amendments to director compensation and board structure, auditor ratification, and a say-on-pay vote for executive compensation.

  • The company proposes to amend the Non-Employee Director Compensation Program to increase cash and equity compensation to the median of peer group companies, aiming to attract and retain qualified directors.

  • A proposal seeks to reduce the board's classified structure from three classes to two, enhancing director accountability and aligning with shareholder interests.

  • Ernst & Young LLP is recommended for ratification as the independent auditor for fiscal year 2025.

  • Shareholders are encouraged to vote electronically or by mail, and may submit questions in advance or during the meeting.

Voting matters and shareholder proposals

  • Proposal One: Re-election of two Class I Directors for three-year terms.

  • Proposal Two: Amendment to increase non-employee director compensation, including higher cash retainers and stock options.

  • Proposal Three: Amendment to reduce board classification from three to two classes, requiring a two-thirds majority.

  • Proposal Four: Ratification of Ernst & Young LLP as independent auditor for 2025.

  • Proposal Five: Non-binding advisory vote to approve 2024 executive compensation.

  • Deadlines for shareholder proposals for the 2026 meeting are specified.

Board of directors and corporate governance

  • The board consists of nine directors (two vacancies), with a majority being independent under Nasdaq rules.

  • Leadership roles are separated: the CEO and Chairman are different individuals.

  • The board has Audit, Compensation, and Nominating & Governance Committees, all composed of independent directors.

  • The board held ten meetings in 2024, with all directors attending at least 75% of meetings.

  • Director qualifications emphasize integrity, experience, and diversity of perspectives.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more